Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Batiraxcept - Aravive

Next Previous
Drug Profile

Batiraxcept - Aravive

Alternative Names: 3D-229; 3D-299; AB-007 - AKSO Biopharmaceutical; Aravive-S6; AVB 500; AVB S6 500; Axl fc fusion protein AVB-S6-500; Ruga-S6; S6-500c

Latest Information Update: 24 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stanford University
  • Developer 3D Medicines; AKSO Biopharmaceutical; Aravive; Aravive Biologics; European Network of Gynaecological Oncological Trial Groups; Gynecologic Oncology Group
  • Class Antifibrotics; Antineoplastics; Antivirals; Immunoglobulin Fc fragments; Immunotherapies; Proteins; Recombinant fusion proteins
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II Urogenital cancer
  • Phase I/II Pancreatic cancer; Renal cell carcinoma
  • Phase I Inflammation; Thrombosis
  • Preclinical Non-small cell lung cancer
  • Discontinued Acute myeloid leukaemia; Cholangiocarcinoma; Fallopian tube cancer; IgA nephropathy; Peritoneal cancer; Renal fibrosis; Solid tumours; Unspecified; Viral infections

Most Recent Events

  • 11 Jun 2025 Aravive Biologics terminates phase I/II trial in Ovarian cancer, Fallopian tube cancer and Peritoneal cancer (Combination therapy, Recurrent, Second-line therapy or greater) in USA (IV) due to PI request (NCT04019288)
  • 04 Feb 2025 Phase-I clinical trials in Inflammation (Parenteral) prior to January 2025 (AKSO Biopharmaceutical Pipeline, January 2025)
  • 04 Feb 2025 Phase-I clinical trials in Thrombosis (Parenteral) prior to January 2025 (AKSO Biopharmaceutical Pipeline, January 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top